D. E. Shaw & Co., Inc. Mersana Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$114 Billion
Q1 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 1,222,623 shares of MRSN stock, worth $2.41 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,222,623

Previous 667,383 83.2%

Holding current value

$2.41 Million

Previous $1.55 Million 253.81%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.16 - $5.94 $1.2 Million - $3.3 Million	555,240 Added 83.2%	1,222,623 $5.48 Million
Q4 2023 Feb 14, 2024	BUY	$1.11 - $2.34 $665,557 - $1.4 Million	599,601 Added 884.6%	667,383 $1.55 Million
Q3 2023 Nov 14, 2023	SELL	$1.06 - $3.91 $973,034 - $3.59 Million	-917,957 Reduced 93.12%	67,782 $86,000
Q2 2023 Aug 14, 2023	SELL	$3.08 - $9.55 $2.53 Million - $7.83 Million	-820,360 Reduced 45.42%	985,739 $3.24 Million
Q1 2023 May 15, 2023	SELL	$4.0 - $7.02 $2.12 Million - $3.72 Million	-529,840 Reduced 22.68%	1,806,099 $7.42 Million

Q4 2022 Feb 14, 2023	SELL	$5.65 - $7.86 $1.63 Million - $2.27 Million	-288,284 Reduced 10.99%	2,335,939 $13.7 Million
Q3 2022 Nov 14, 2022	BUY	$4.63 - $8.0 $2.99 Million - $5.17 Million	646,293 Added 32.68%	2,624,223 $17.7 Million
Q2 2022 Aug 15, 2022	SELL	$2.84 - $5.0 $320,738 - $564,680	-112,936 Reduced 5.4%	1,977,930 $9.14 Million
Q1 2022 May 16, 2022	BUY	$3.74 - $6.63 $5.41 Million - $9.59 Million	1,445,963 Added 224.21%	2,090,866 $8.34 Million
Q4 2021 Feb 14, 2022	BUY	$5.48 - $9.86 $3.27 Million - $5.88 Million	596,298 Added 1226.82%	644,903 $4.01 Million
Q3 2021 Nov 15, 2021	BUY	$8.56 - $14.47 $72,931 - $123,284	8,520 Added 21.25%	48,605 $458,000
Q2 2021 Aug 16, 2021	SELL	$13.28 - $18.07 $1.51 Million - $2.06 Million	-113,986 Reduced 73.98%	40,085 $544,000
Q1 2021 May 17, 2021	SELL	$15.31 - $26.52 $5.97 Million - $10.3 Million	-389,804 Reduced 71.67%	154,071 $2.49 Million
Q4 2020 Feb 16, 2021	SELL	$16.84 - $27.59 $3.5 Million - $5.73 Million	-207,851 Reduced 27.65%	543,875 $14.5 Million
Q3 2020 Nov 16, 2020	SELL	$16.2 - $25.7 $4.44 Million - $7.05 Million	-274,224 Reduced 26.73%	751,726 $14 Million
Q2 2020 Aug 14, 2020	BUY	$5.24 - $23.4 $5.25 Million - $23.5 Million	1,002,801 Added 4331.94%	1,025,950 $24 Million
Q1 2020 May 15, 2020	SELL	$4.41 - $9.28 $551,241 - $1.16 Million	-124,998 Reduced 84.37%	23,149 $135,000
Q4 2019 Feb 14, 2020	SELL	$1.45 - $6.73 $135,457 - $628,709	-93,419 Reduced 38.67%	148,147 $848,000
Q3 2019 Nov 14, 2019	SELL	$1.54 - $4.2 $5,005 - $13,650	-3,250 Reduced 1.33%	241,566 $382,000
Q2 2019 Aug 14, 2019	BUY	$3.84 - $6.4 $499,983 - $833,305	130,204 Added 113.6%	244,816 $991,000
Q1 2019 May 15, 2019	BUY	$3.51 - $7.3 $402,288 - $836,667	114,612 New	114,612 $603,000
Q1 2018 May 15, 2018	SELL	$13.56 - $18.48 $230,981 - $314,788	-17,034 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$14.95 - $19.9 $254,658 - $338,976	17,034	17,034 $280,000

Others Institutions Holding MRSN

# of Institutions

128

Shares Held

118M

Call Options Held

68.1K

Put Options Held

140K

View Full List

About Mersana Therapeutics, Inc.

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $191M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

More about MRSN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account